Division of Pulmonary Medicine, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan, ROC.
Department of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan, ROC.
Thorac Cancer. 2023 Jul;14(21):2007-2017. doi: 10.1111/1759-7714.14982. Epub 2023 May 30.
Lung cancer, especially non-small cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide. Vincristine (VCR) is a chemotherapeutic agent for lung cancers; however, its effectiveness is limited by side effects and the development of drug resistance. Patchouli alcohol (PA), from Pogostemon cablin extract, is known to possess anti-inflammatory and anticancer properties. In this study, we investigated the role of PA in inducing reactive oxygen species (ROS)-mediated DNA damage in A549 and VCR-resistant A549/V16 NSCLC cells.
The anticancer potential of PA was studied using the MTT assay, colony formation, flow cytometry analysis, western blotting, DCFDA staining, immunofluorescence staining, and TUNEL assay techniques.
The intracellular ROS levels were enhanced in PA-treated cells, activating the CHK1 and CHK2 signaling pathways. PA further inhibited proliferation and colony-forming abilities and induced cell cycle arrest at the G /G phase by regulating p53/p21 and CDK2/cyclin E1 expression. Moreover, PA increased the percentage of cells in the subG phase and induced apoptosis by activating the Bax/caspase-9/caspase-3 intrinsic pathway. In addition, drug resistance (p-glycoprotein) and cancer stem cell (CD44 and CD133) markers were downregulated after PA treatment. Furthermore, combining PA and cisplatin exhibited synergistic inhibitory activity in A549 and A549/V16 cells.
PA induced ROS-mediated DNA damage, triggered cell cycle arrest and apoptosis, attenuated drug resistance and cancer stem cell phenotypes, and synergistically inhibited proliferation in combination with cisplatin. These findings suggest that PA has the potential to be used for the treatment of NSCLC with or without VCR resistance.
肺癌,特别是非小细胞肺癌(NSCLC),是全球癌症相关死亡的主要原因之一。长春新碱(VCR)是一种用于肺癌的化疗药物;然而,其疗效受到副作用和耐药性发展的限制。从广藿香中提取的广藿香醇(PA)已被证明具有抗炎和抗癌特性。在这项研究中,我们研究了 PA 在诱导 A549 和 VCR 耐药 A549/V16 NSCLC 细胞中活性氧(ROS)介导的 DNA 损伤中的作用。
使用 MTT 测定法、集落形成、流式细胞术分析、western blot 分析、DCFDA 染色、免疫荧光染色和 TUNEL 测定技术研究 PA 的抗癌潜力。
PA 处理的细胞中细胞内 ROS 水平升高,激活 CHK1 和 CHK2 信号通路。PA 进一步抑制增殖和集落形成能力,并通过调节 p53/p21 和 CDK2/cyclin E1 表达诱导细胞周期停滞在 G1/G0 期。此外,PA 通过激活 Bax/caspase-9/caspase-3 内在途径增加亚 G 期细胞的百分比并诱导细胞凋亡。此外,PA 处理后,耐药(p-糖蛋白)和癌症干细胞(CD44 和 CD133)标志物下调。此外,PA 与顺铂联合使用在 A549 和 A549/V16 细胞中表现出协同抑制活性。
PA 诱导 ROS 介导的 DNA 损伤,引发细胞周期停滞和细胞凋亡,减弱耐药性和癌症干细胞表型,并与顺铂协同抑制增殖。这些发现表明,PA 具有用于治疗 NSCLC 或 VCR 耐药性的潜力。